Aarti Drugs Q4 Revenue Up 6% YoY, PAT Down 12%

Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore, a 6% YoY growth, while PAT declined 12% to ₹55.3 crore.
EBITDA was flat YoY at ₹96.6 crore, with margins contracting 60 bps to 13.4%, but showed strong 72% QoQ growth from Q3.
Full-year FY26 revenue grew 7% to ₹2,567.7 crore, with PAT up 16% to ₹194.9 crore, supported by formulations and specialty chemicals growth.
Management cited startup losses from new facilities and domestic antibiotic market weakness as headwinds, with sequential improvement driven by Sayakha facility scale-up.